Recombinant Mouse IFN-beta protein (His Tag)
种属
Mouse
纯度
>90 %, SDS-PAGE
标签
C-His
生物活性
未测试
验证数据展示
产品信息
| 纯度 | >90 %, SDS-PAGE |
| 内毒素 | <0.1 EU/μg protein, LAL method |
| 生物活性 | Not tested |
| 来源 | HEK293-derived Mouse IFN-beta protein Ile22-Asn182 (Accession# P01575) with a His tag at the C-terminus. |
| 基因ID | 15977 |
| 蛋白编号 | P01575 |
| 预测分子量 | 23.8 kDa |
| SDS-PAGE | kDa, reducing (R) condition |
| 组分 | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| 复溶 | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| 储存条件 |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| 运输条件 | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
背景信息
Interferon beta (IFN-beta) is a cytokine that is naturally produced by the immune system in response to biological and chemical stimuli. It signals by binding to the heterodimeric type I IFN receptor composed of the IFNAR1 and IFNAR2 chains, and regulates the expression of a plethora of genes by means of the classical JAK/STAT and other pathways. Interferon beta (IFN-beta) has been shown in several clinical trials to have efficacy in multiple sclerosis. Interferon beta gene therapy is expected to become widely available for clinical use in cancer patients, and this new strategy might be extended to molecular targeting therapy, or used in combination with cell therapy or other therapies.
参考文献:
1. M Haji Abdolvahab.et al.(2016) Int Rev Cell Mol Biol.326:343-72. 2. Revel M.et al. (2003) Pharmacol Ther.100(1):49-62. 3.Jun Yoshida.et al. (2004) Cancer Sci.95(11):858-65.